Fusion Antibodies PLC Ordinary Shares (FAB)

Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

6.50p

Buy

7.00p

arrow-up0.45p (+7.14%)

Fusion Antibodies PLC is engaged in the research, development and manufacturing of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases.
Prices updated at 16 May 2025, 16:28 BST
| Prices minimum 15 mins delay
|
Prices in GBX
FTSE All-Share
arrow-up0.59%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Simon Gordon Douglas
CEO
Dr. Adrian Robert Kinkaid
Most recent earnings
31 Mar 2024
Fiscal year end
31 Mar 2024
Employees
24
Head office
1 Springbank Road
Belfast
United Kingdom
BT17 0QL
mobile
+44 2890432800
letter
info@fusionantibodies.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Dr. Simon Gordon Douglas
Non-Executive Director, Chairman
---0.02m-
Mr. Colin James Walsh
Non-Executive Director
-----
Mr. Matthew Paul Baker
Non-Executive Director
---0.02m-
Dr. Richard John Buick
Executive Director, Chief Scientific Officer
-----
Dr. Adrian Robert Kinkaid
Executive Director, Chief Executive Officer
-----

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
Unicorn Asset Management Ltd6,397,2900.21393--30 Apr 20256.10
Unicorn AIM VCT Series 3 ORD6,397,2900.21393--30 Apr 20256.10
Maven Renovar VCT PLC4,562,5000.11192180720165.59001430 Apr 20254.35
Octopus Investments Limited1,457,6350.04931879857-30 Apr 20251.39
Baronsmead Second Venture Trust935,4840.0134813548416.935530 Apr 20250.89

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
12 May 2025PurchaseMr. Colin James Walsh6.1013,5003,109,1122.74Fees
12 May 2025PurchaseDr. Simon Gordon Douglas6.103,7501,061,0620.94Fees
12 May 2025PurchaseMr. Matthew Paul Baker6.103,375292,9020.26Fees
06 May 2025PurchaseDr. Adrian Robert Kinkaid6.186,180850,0000.75-
22 Oct 2024PurchaseMr. Colin James Walsh4.1513,5002,887,8013.03Fees
22 Oct 2024PurchaseDr. Simon Gordon Douglas4.157,500999,5871.05Fees
22 Oct 2024PurchaseMr. Matthew Paul Baker4.153,375237,5750.25Fees
16 Oct 2024PurchaseDr. Adrian Robert Kinkaid4.183,504750,0000.79-
09 Sep 2024PurchaseDr. Richard John Buick3.273,1061,000,0001.05-
04 Sep 2024PurchaseDr. Adrian Robert Kinkaid3.173,804666,2720.70-
22 Jul 2024PurchaseDr. Simon Gordon Douglas3.214,815818,8650.86-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.